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Background: Intracerebral hemorrhage (ICH) is a fatal subtype of stroke that lacks effective treatments. Angiogenesis
following ICH is an important response mediating brain recovery and repair. Phosphorylation of vascular endothelial
growth factor receptor 2 (pVEGFR2) via PI3K/Akt signaling plays a key role in mediating cellular processes involved in
repair, such as mitogenesis, angiogenesis, and vascular permeability. This study aimed to investigate the potential
effects of Buyang Huanwu Decoction (BYHWD), a traditional Chinese medicine formula, on angiogenesis by VEGFR2
activation through the phosphatidylinositol 3 kinase (PI3K)/Akt signaling pathway in a mouse model of ICH.
Methods: Adult male Kunming mice (n = 50) were randomly assigned into sham and ICH-operated groups and treated
with one of the followings SU5416 (VEGFR2 inhibitor), BYHWT and BYHWT + SU5416. ICH was induced in mice by
injecting collagenase (type VII) into the right globus pallidus of the mouse brain. BYHWD (4.36 g/kg) was administrated
in mice by intragastric infusion. Neurological function was evaluated in mice by a modified Neurological Severity
Scores (mNSS) as well as corner turn and foot-fault tests. Angiogenesis was examined by intraperitoneal injection
of 5-bromodeoxyuridine (BrdU) in mice to quantify new brain vessel growth. SU5416 treatment and assessment of
VEGFR2 phosphorylation as well as alterations in PI3K/Akt signaling were performed to determine whether the effect of
BYHWD on angiogenesis was partly mediated by phosphorylation of VEGFR2 via the PI3K/Akt signaling pathway.
Results: We show that BYHWD treated mice exhibited (i) significantly better recovery from neurological dysfunction,
(ii) increased BrdU+ nuclei in vWF+ dilated brain vessels and (iii) higher VEGFR2 phosphorylation immunoreactivity
in brain microvessels (P <0.05), (iv) higher expression of PI3K and pAkt at the protein level (P <0.05) when compared to
untreated ICH mice. These beneficial effects were reversed by SU5416 (P <0.05).
Conclusions: BYHWD promoted neurological recovery and angiogenesis after ICH in mice by enhancing VEGFR2
phosphorylation through the PI3K/Akt signaling pathway.
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Spontaneous intracerebral hemorrhage (ICH) is one of
the most lethal types of stroke [1] with the highest mor-
tality and morbidity [2]. Conventional therapies for ICH
consist of hematoma removal, edema attenuation and
intracranial pressure reduction. However, the effective-
ness of ICH therapy is far from satisfactory [3]. It is
therefore important and necessary to explore new strat-
egies for ICH treatment.
Recent studies on pathophysiological mechanisms of
ICH impairment mainly focus on secondary brain injury
and neuronal death caused by inflammation iron accu-
mulation. Inflammation is mediated by inflammatory
cells (blood-derived leukocytes, macrophages, microglia,
astrocytes, mast cells) activation and their local release
of cytokines, proteases, prostaglandins, proteases and so
on [4,5]. Excessive iron accumulation after ICH due to
heme degradation can stimulate reactive oxygen species
(ROS) formation causing neurotoxicity and neurodegen-
eration [6]. Despite these impairment factors, there are
also endogenous mechanisms of brain self-repair after
stroke, which include angiogenesis.
Normal brain function requires unrestricted blood
flow to supply glucose and oxygen to neurons. Following
a damaging ICH event, new microvasculature formation
is required for brain recovery by promoting oxygen and
metabolite exchange and removing necrotic debris [7,8].
Angiogenesis refers to the establishment of new vessels
from pre-existing vasculature by such processes as
sprouting, pruning and intussusception. It starts with
stimulation of endothelial cells (ECs) that line the lu-
minal surface of blood vessels, and occurs under both
physiological and pathological conditions [9,10]. During
angiogenesis, a highly regulated process, the most potent
pro-angiogenic signaling cascades are initiated by vascular
endothelial growth factor (VEGF) binding to EC-resident
VEGF receptors (VEGFR) like VEGFR1, VEGFR2 and
VEGFR3 [9]. Of these, VEGFR2 transduces angiogenic sig-
nals after binding VEGF, while VEGFR1 transduces only
weak signals for ECs growth and survival, and VEGFR3 is
generally restricted to lymphatic endothelia [11]. VEGF
expression has been evaluated and shown to be an import-
ant component of the response after brain injury [12]. We
have previously demonstrated that angiogenesis can occur
following ICH in brains, and are able to specifically detect
VEGF and VEGFR2 around the hematoma [13].
VEGF binding to VEGFR2 leads to the receptor
dimerization, protein kinase activation, autophosphoryl-
ation, and finally, the initiation of several signaling cascades
[14]. Amongst the endothelial cell signaling pathways,
PI3K/Akt is known to be a major regulator of proliferation,
migration and survival of ECs as well as vascular perme-
ability. VEGFR2 activation is believed to be the “switch”
that activates the downstream PI3K/Akt signaling cascade[15]. SU5416, a potent selective inhibitor of VEGFR2 tyro-
sine kinase catalysis, 3-[2, 4- dimethylpyrrol-5-yl methyli-
denyl] -2-indolinone, has been shown to reduce tumor
angiogenesis and growth in animal models [16-18].
Traditional Chinese medicine (TCM) has been shown to
have positive effects in stroke [19]. As a classical TCM pre-
scription for stroke, Buyang Huanwu Decoction (BYHWD)
shows substantial neuroprotective, pro-angiogenic and
function-improving effects in animal models of focal cere-
bral ischemia [20-22], while also possessing desirable clin-
ical efficacy for both hemorrhagic and ischemic stroke [23].
Furthermore, we have shown previously that BYHWD
could upregulate VEGF and VEGFR2 after ICH [24]. Since
VEGFR2 activation can efficiently stimulate angiogenesis
[25], we hypothesized that BYHWD could likewise pro-
mote angiogenesis in the ICH model through VEGFR2
stimulation. Therefore, we were interested in studying the
effects of BYHWD on the recovery of the brain after
hemorrhagic injury as well as VEGFR2 phosphorylation
and its signaling pathway mechanisms.Methods
Animal preparation
Studies were carried out on adult male Kunming mice
(25–30 g, 8–10 weeks of age) obtained from the Experi-
mental Animal Science Center of Central South University
(CSU). All animals were housed under identical condi-
tions (room temperature at 25°C, 12 h light–dark cycle)
and allowed free access to food and water. The experi-
mental protocol was performed in compliance with guide-
lines of CSU and the NIH Guide for the Care and Use of
Laboratory Animals (NIH Publications No. 80–23) and
was approved by the Institutional Animal Care and Use
Committee of CSU (2010-xy-0106).BYHWD preparation
According to the original prescription from the “TCM
Prescriptions Dictionary”, BYHWD consists of seven
Chinese herbs (Table 1). All dried crude herbs were
purchased from the Chinese Medicinal Pharmacy of
Xiangya Hospital, Changsha, China. Voucher speci-
mens were prepared and deposited at the Laboratory
of Institute of Integrative Medicine, Central South
University. To maintain the consistency of the herbal
chemical ingredients, all components were obtained
from the original sources and extracted according to
standards listed in the National Pharmacopoeia of
China. The herbs were cut, mixed, and decocted by
boiling in distilled water at 100°C for 30 min. The
solution was then freeze-dried under vacuum, and
ground into powder (yield: 14.3%). The powder was
dissolved in distilled water to a final concentration of
0.132 g/ml.
Table 1 Components of the buyang huanwu decoction
Latin name Family English name Chinese name Part used Batch number
Radix astragali Leguminosae Astragalusmongholicus Huang qi Root 091201
Radix paeoniaeRubra Ranunculaceae Red peony root Chi shao Root 091214
Radix angelicaeSinensis Umbelliferae Angelica root Dang gui Root 091206
RhizomaLigusticiChuanxiong Umbelliferae Sichuan lovage rhizome Chuanxiong Root 100304
FlosCarthami Feverfew Carthamustinctorius Hong hua Flower 100329
Semen persicae Rosaceae Peach seed Tao ren Seed 091218
PheretimaAspergillum Megascolecidae Earthworm (Lumbricus) Di long Whole animal 091222
In the order listed above, the herbs were combined in a 60:6:4.5:3:3:3 ratio (dry weight).
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After fasting overnight, the mice were anesthetized with
5% chloral hydrate (300 mg/kg IP) and then fixed on a
stereotaxic frame (Stoelting Co., Chicago, IL, USA) in
the prone position. Following a scalp incision and dril-
ling of a small cranial bur hole, 0.075 U of collagenase
(type VII) in 0.5 μl 0.9% sterile saline was slowly injected
into the right globus pallidus (0.5 mm posterior, 2.0 mm
lateral to bregma and 4.0 mm ventral to cortical surface)
of the mouse brain, using a 1-μl Hamilton syringe. The
infusion was administered over 2 min, with the needle
kept in place for an additional 5 minutes thereafter. In
the sham-operated group, 0.5 μl 0.9% sterile saline with-
out collagenase was injected into the same site.Experimental protocol
Mice were randomly assigned to both sham and ICH op-
erated groups and treated with one of the followings:
SU5416, BYHWT and BYHWT+ SU5416 (n = 10, per
group). Twenty-four hours after ICH induction, 5-
bromodeoxyuridine (BrdU, Roche, Indianapolis, IN, USA)
was given (50 mg/kg/d) by intraperitoneal injection. The
SU5416-treated and BYHWT+ SU5416-treated groups
were administrated with SU5416 (10 mg/kg, Santa Cruz,
Dallas, Texas, USA) in distilled water (DW) containing
1% dimethyl sulfoxide (DMSO, Calbiochem, La Jolla,
CA, USA) by intraperitoneal injection. Control groups
received 1% DMSO in their respective cocktails.
BYHWD (4.36 g/kg) was given to BYHWD-treated and
BYHWT+ SU5416-treated groups intragastrically. Equal
volume of DW was given to all other groups. The dose of
BYHWD of 4.36 g/kg was chosen from the preliminary
tests for the recovery of motor function in ICH animals
(data not shown). Administration of drug treatments was
performed 24 h after ICH induction, once a day for 7 days.Behavioral tests
Behavioral tests were carried out at day 1, 3, 7 after ICH.
Two observers, blinded to the experimental design,
scored the animals independently and the scores were
averaged. The tests were composed of a modifiedNeurological Severity Score (mNSS) [26], corner turn
test [27] and foot-fault test [28].
1) Neurological score: An eighteen point neurological
score was employed: (normal score, 0; maximal
deficit score, 18). For severity scores of injury, 1
score point is awarded for the inability to perform
the test or for the lack of a tested reflex; thus, the
higher score, the more severe the injury [26].
2) Corner turn test: Mice were allowed to proceed into
a corner, the angle of which was 30 degrees. To exit
the corner, individual mice could turn either left or
right, and the direction taken was then recorded.
This was repeated 10 to 15 times per animal, with at
least 30 seconds between trials, and the percentage
of right turns was calculated [27].
3) Foot-fault test: Mice were tested for placement
dysfunction of forelimbs with the modified
foot-fault test. Animals were set on an elevated
grid surface (85.8 × 2.5 cm2, with grids of different
sizes) and placed their paws on the wire while
moving along the grid. With each weight-bearing
step, the paw may fall or slip between the wire.
Each such event was recorded as a foot fault. The
total number of steps (movement of each forelimb)
that the mice used to cross the grid was counted,
and the total numbers of foot faults for the left
forelimb were recorded. Data are presented as the
percentage of foot faults per the total number of
steps [28].
Specimen preparation
Randomly chosen animals from each group were deeply
anesthetized with chloral hydrate (300 mg/kg). For im-
munohistochemistry, animals were transcardially per-
fused with 0.9% saline followed by 250 ml ice-cold 4%
paraformaldehyde in 0.1 M phosphate buffer (PB,
pH 7.4). The excised brains were post-fixed in the same
fixative for 2 h, then transferred to 20% and then 30%
sucrose in 0.1 M PB (pH 7.4) sequentially at 4°C until
sinking. Brains were cut into 30 μm coronal sections
at −20°C with a cryostat (CM1900, Leica, Germany), some
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line (pH 7.4) and stored at 4°C.
For Western blot analysis, mice were transcardially
perfused with ice-cold 0.9% saline and then sacrificed by
decapitation. The brains were immediately removed, and
the tissues in the striatum, adjacent to the hematoma
without the needle track, were dissected and stored in
liquid nitrogen tank.
Immunohistochemical analysis
To detect proliferating cerebral microvascular ECs, im-
munohistochemical double-staining was performed. Sec-
tions were pretreated to denature DNA as follows: after
immersion in 50% formamide/2× saline-sodium citrate
buffer (SSC, pH 7) at 65°C for 2 h, sections were washed
in 2× SSC for 10 min then incubated in 2 N HCl at 37°C
for 30 min. After nonspecific antigen blocking in 5%
bovine serum albumin (BSA, Sigma-Aldrich, St. Louis,
MO, USA), sections were incubated with a mouse anti-
BrdU (1:200, Neomarker, Fremont, CA, USA) at 4°C over-
night, then with biotinylated anti-mouse IgG (1:200, Vector
Laboratories, Burlingame, CA, USA) for 1 h at 37°C,
followed by avidin-biotin-peroxidase complex (ABC)
(1:100, Vector) for 1 h at 37°C. Immunoreactivity was
visualized with diaminobenzidine (DAB, Boster Biotech,
Wuhan China). For labeling cerebral EC’s, we used a
rabbit anti-von Willebrand factor (vWF, 1:400, Chemicon
International, Temecula, CA, USA) primary antibody in
concert with ammonium nickel sulfate to enhance
visualization. BrdU+/vWF+ nuclei close to the hematoma
were counted in four 250 × 250 μm areas in five sections
through the stroke for each animal at × 40 objective mag-
nification using image J analysis software, by a researcher
blind to the experimental design as previously described.
Data were presented as the number of nuclei per mm2
(N/mm2).
For expression of phospho (p)-VEGFR2, sections were
brought to room temperature and incubated in 3% H2O2
for 15 min. After washing sections 3 times in phosphate-
buffered saline for 5 min each, non-specific binding was
blocked in 5% bovine serum albumin (Sigma Aldrich)
for 1 h at 37°C. Sections were then incubated overnight
at 4°C with a pVEGFR2 rabbit mAb (diluted 1:100, Cell
Signaling Technology, Boston, MA, USA), with a bio-
tinylated anti–rabbit immunoglobulin G (1:200) for 2 h,
and then with avidin-biotin-peroxidase complex (1:100,
Vector) for 1 h at 37°C. Immunoreactivity was visualized
with diaminobenzidine (DAB, Boster Biotech). Areas of
immunoreactivity were measured using Qwin software
to determine gray scale.
To determine whether pVEGFR2 was expressed in ECs,
immunofluorescence double labeling was performed. Tis-
sue sections were first incubated at 4°C for 48 h with a
mixture of 2 primary antibodies: mouse anti–vWF (1:200,Chemicon Int) and either of the rabbit anti-phospho-
VEGFR2 (1:100). The following secondary antibodies were
then used: fluorescein isothiocyanate–conjugated goat
anti–mouse antibody (1:50, Santa Cruz Biotech, Santa
Cruz, CA, USA) for vWF and rhodamine-conjugated don-
key anti-rabbit antibody (1:50, Santa Cruz) for pVEGFR2
detection. For a negative control, 1% bovine serum albu-
min was used instead of the primary antibody. These sec-
tions were scanned using a laser confocal microscope
(LSM-510, Zeiss).
Western blot assay
Tissues from the right globus pallidus were homoge-
nized in RIPA buffer containing 50 mM Tris–HCl
(pH 7.4), 150 mM NaCl, 1% sodium deoxycholate, 1%
NP-40, 0.1% lauryl sodium sulfate, 1 mM phenylmethyl-
sulfonyl fluoride (PMSF), and 1% inhibitor cocktail (Bio-
Basic Inc, Markham, ON, Canada), and the homogenate
was centrifuged at 14,000 g for 30 min. Proteins (50 μg)
from the supernatant of each sample were then sepa-
rated by SDS-PAGE and transferred onto polyvinylidene
difluoride membranes, which were subsequently blocked
in TBST buffer containing 20 mMTris–HCl, 5% skim
milk, 150 mM NaCl, and 0.05% Tween 20 (pH 7.5) for
2 h at room temperature. Membranes were incubated
with either goat anti-p-VEGFR2 (1:200, Santa Cruz Bio-
tech), rabbit-anti-VEGFR2 (1:1000, Abcam, Cambridge,
UK), rabbit anti-PI3K (1:2000, Millipore-Merck, Darmstadt,
GER), rabbit anti-Akt (1:2000, Cell Signaling Tech), rabbit
anti-p-Akt (1:2000, Cell Signaling Tech) or mouse anti-
actin (1:5000, Abcam) antibodies for overnight at 4°C. Sub-
sequently, membranes were incubated with horseradish
peroxidase-conjugated anti-goat IgG (1:5000, Promega,
Madison, WI, USA), anti-rabbit IgG antibody (1:5000, Pro-
mega) or anti-mouse IgG (1:5000, Promega) antibodies for
2 h at room temperature. The immunopositive bands were
visualized by chemiluminescence detection using Super-
SignalWest Pico Chemilumescent Substrate (Thermo) and
a Bio-Rad ChemiDoc XRS digital documentation system
(Bio-Rad, Hercules, CA, USA). The optical density (OD) of
each band was normalized against that of β-actin.
Statistical analysis
All data in this study are presented as mean ± standard
deviation (SD). Data were analyzed with Student’s t test
and one-way analysis of variance (ANOVA), followed by
Scheffe’s post hoc test. Differences were considered sig-
nificant at P <0.05.
Results
Effect of BYHWD on the neurological outcomes of ICH mice
On the first day, all four groups subjected to
collagenase-induced ICH showed similar neurological
deficits, while the sham-operated animals were almost
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at later time points revealed that the neurological sta-
tus of both the ICH group and BYHWD-treated group
improved over time (a decrease in the mNSS) with the
former significantly higher than the latter (more than 2
points higher at day 3 and 7, P <0.05). However, the
scores were significantly (P <0.05) higher in the
SU5416-treated and BYHWD + SU5416-treated group
compared with those in the ICH group (about 3 points
higher at day 3 and 7) and BYHWD-treated group
(more than 4 points higher at day 3 and 7), respectively
(Figure 1A, P <0.05, P <0.01).
At day 3, the ICH group (about 20%) and BYHWD-
treated group (about 30%) performed significantly better
in the corner turn test than their inhibitor-treated coun-
terparts, respectively (P <0.05, P <0.01). BYHWD-treated
mice significantly outperformed ICH mice (about 20%
lower at day 3 and 7, respectively) (Figure 1B, P <0.05).
Similarly, BYHWD-treated mice significantly outper-
formed ICH mice in the foot-fault test (about 20% lower
at day 3 and 7, respectively). Treatment with SU5416Figure 1 Effect of BYHWD on neurological outcomes in mice after ICH.
a significantly lower mNSS (A) as well as better performance in corner turn (B
differences were found between BYHWD-treated group and ICH group. The p
compared with the total number of steps. Data represent the mean ± SD, n =
one-way analysis of variance (ANOVA), followed by Scheffe’s post hoc test.worsened the response of the foot-fault test in BYHWD-
treated (about 40% higher at day 3 and 7, respectively)
and ICH mice (about 30% higher at day 3 and 7, respect-
ively) (Figure 1C, P <0.01, P <0.05).
BYHWD promoted angiogenesis via upregulating pVEGFR2
The effects of BYHWD on pVEGFR2 expression and
angiogenesis in the brain of mice at 7 days after ICH
were further examined using the double-labeling immu-
nohistochemistry (Figure 2A-M). The results showed
that pVEGFR2 expression was primarily localized to the
vWF-immunoreactive ECs (Figure 2A), while pVEGFR2-
positive microvessels and BrdU+ nuclei in vWF+ vessels
were rarely observed in either hemisphere of the sham-
operated animals (Figure 2B, H, G and M). In contrast,
pVEGFR2-positive microvessels and BrdU-labeled ves-
sels in the ICH group appeared to be dilated and most
were present in the perihematomal tissue (Figure 2C, I, G
and M). We observed fewer vessels positive for pVEGFR2
and BrdU in the SU5416-treated animals (Figure 2D, J, G
and M). In comparison, significantly more pVEGFR2-Mice in the ICH group and BYHWD-treated group (3 d and 7 d) showed
) and foot-fault (C) tests than their inhibitor-treated counterparts. Similar
ercentage of right turns (B) and foot faults (C) from each group was
10. *, P <0.05; **, P <0.01). Data were analyzed with Student’s t test and
Figure 2 (See legend on next page.)
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Figure 2 BYHWD upregulates pVEGFR2 expression and angiogenesis following ICH. Double-labeling revealed that immunoreactivity for
pVEGFR2 (red, arrow) overlapped with vWF+ cells (green, arrow) (A). pVEGFR2-positive microvessels and BrdU+ nuclei (brown, arrow) were shown
in vWF+ vessels (blue) in either hemisphere of the sham-operated animals (B and H), ICH group (C and I), SU5416-treated (D and J), BYHWD- treated
(E and K) and BYHWD+ SU5416-treated (F and L) groups. The immunoreactivity of p-VEGFR2 (G) and the number of BrdU+/vWF+ (M) nuclei were
compared between BYHWD-treated and non-treated groups.
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found in the vicinity of the lesion in the BYHWD treat-
ment groups (Figure 2E, K, G and M).
In order to verify whether BYHWD promotes VEGFR2
activation, thereby inducing angiogenesis, SU5416 was
administered to ICH animals in combination with
BYHWD. We found that fewer pVEGFR2-positive
microvessels and BrdU+ nuclei in vWF+ dilated vessels were
present around the hemotoma of the BYHWD+ SU5416-
treated group, compared with those of the BYHWD-treated
group (Figure 2F, L, G and M).
Finally, we performed western blots to determine the
effects of BYHWD on the phosphorylation of VEGFR2,
and impact on the PI3K/Akt signaling pathway. The
results showed that low levels of total VEGFR2 and
pVEGFR2 were observed in the sham-operated brains
(Figure 3N). Collagenase-induced ICH increased the
activation ratio of VEGFR2, which was similar to that of
the BYHWD group. This high ratio could be reversed by
SU5416 (P <0.05, Figure 3N and O). Despite the similar
activation ratio of VEGFR2 in both ICH and BYHWDFigure 3 BYHWD upregulates pVEGFR2 expression and angiogenesis
showed that the effects of ICH, SU5416 and BYHWD on the protein levels o
(N and Q). The ratios of pVEGFR2/VEGFR2 (O), pVEGFR2/β-actin, VEGFR2/β-ac
ICH and BYHWD with or without SU5416 (mean ± SD, n = 5, * P <0.05, ** P <0
analysis of variance (ANOVA), followed by Scheffe’s post hoc test.administrated animals, the protein levels of total and acti-
vated VEGFR2 in the BYHWD group were about 2-fold
higher than that of the ICH group (P <0.05, Figure 3P).
BYHWD promoted angiogenesis via pVEGFR2 mediated
PI3k/Akt signaling pathway
To further verify whether VEGFR2 activation is required
for PI3K/Akt signaling transduction in BYHWD promoted
angiogenesis, we examined the effect of SU5416 on the ex-
pression PI3K and the ratios of pAkt/Akt (Figure 3Q). The
protein expression of PI3K and the ratios of pAkt/Akt were
higher in the ICH group than that in SU5416-treated
group (P <0.05, Figure 3R and S). These positive effects
were further increased by BYHWD treatment (P <0.05,
Figure 3R and S). However, the increased expression of
PI3K and pAkt induced by BYHWD were markedly inhib-
ited by SU5416 (P <0.05, Figure 3R and S).
Discussion
Our results demonstrate for the first time that blockade
of VEGFR2 phosphorylation by SU5416 could alsovia the PI3K/Akt signaling pathway. A representative immunoblot
f pVEGFR2, VEGFR2, PI3K, pAkt and Akt at the ipsilateral basal ganglion
tin (P), PI3K/β-actin (R) and the ratios of pAkt/Akt (S) were compared in
.01). Bar = 50 μm. Data were analyzed with Student’s t test and one-way
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ICH mouse brains and impede the amelioration of
neurological function. Importantly, our results showed
that BYHWD upregulated pVEGFR2 expression and in-
creased the activation of the PI3K/Akt pathway, thus
promoting angiogenesis and accelerating the recovery of
neurological function. These effects were reversed by
SU5416 treatment. These data supported that the under-
lying mechanisms of pro-angiogenic function of BYHWD
might be involved with the enhancement of VEGFR2
phosphorylation through the PI3K/Akt pathway following
hemorrhagic stroke.
VEGFR-2 is a type III transmembrane kinase receptor,
which is mainly expressed in vascular and lymphatic
endothelial cells. The critical role of VEGFR2 is demon-
strated by the fact that VEGFR2−/− mice die at E8.5-9.5
due to defective development of yolk-sac blood islands,
endothelial cells and hematopoietic cells [14]. Increased
expression of VEGF and VEGFR2 in the basal ganglion
lesion and proliferating ECs after ICH have been re-
ported in our previous study, and their mRNAs are per-
sistently elevated [13]. It is believed that VEGFR2
activation is a key step in regulating EC responses [29].
Suppression of VEGFR2 activity can enhance tumor re-
gression and decrease vascular length and density as well
as tumor vascularity. Additionally, inhibition of VEGFR2
signaling in cerebral ischemia and traumatic brain injury
can aggravate brain injury by increasing cell death, and
reducing EC proliferation [30-32]. Binding and activation
of PI3K is required for phosphorylation of VEGFR2 at
Tyr-801 and Tyr-1175 [33]. Thus, Akt appears to be crit-
ical for VEGF actions and a critical downstream target
of PI3K. Activation of Akt was shown to promote angio-
genic signals that can directly induce angiogenesis [34].
LY294002, a PI3K/Akt inhibitor, can also decrease EC
proliferation and cell cycle progression [35].
To elucidate the potential role of VEGFR2 activation
in angiogenesis in a mouse model of ICH, we exploited
the VEGFR2 inhibitor, SU5416 in our studies. This syn-
thetic molecule contains an unsubstituted oxindole core
and a dimethyl pyrrole attached to the indolin-2-one at
the C3 position. Functioning as adenine mimetics, it acts
as a competitive inhibitor at the catalytic domain of the
tyrosine kinase, thus blocking the interaction between
VEGF and VEGFR2 [17,36]. Immunohistochemistry re-
vealed that the pVEGFR2 immunoreactivity in microves-
sels and BrdU-labeled nuclei in vessels adjacent to
hematoma in the ICH group exceeded those in the
SU5416-administrated group. Western blot also revealed
that ICH increased the total and pVEGFR2 protein levels
which were further evaluated by BYHWD treatment. Al-
though BYHWD administration had a similar activation
ratio of VEGFR2 to that of the ICH, it increased almost
two fold of total and activated VEGFR2 level over theICH. Moreover, VEGFR2 activation could be reversed by
SU5416 in both ICH and BYHWD treatment groups.
This agreed with a prior study on experimental brain
contusions showing that the specific receptor inhibitor
decreases capillary density via downregulation of pVEGFR2
[31]. Protein levels of downstream signaling molecules
PI3K and pAkt showed a similar trend with pVEGFR2
across all of the five groups. This data suggested that acti-
vation of VEGFR2 was necessary for PI3K/Akt signaling
transduction, and consistent with the report of Fournier
et al. that SU5416 administration decreased the protein
level of pAkt in the rat brain with VEGF microinfusion
[37]. These results altogether suggested that upregulation
of pVEGFR2 and coincident activation of PI3K/Akt path-
way was partly involved in the ICH-induced angiogenesis.
BYHWD, a traditional Chinese herbal prescription, has
been used to treat paralysis and stroke in China for
centuries [21]. We have previously demonstrated that
VEGFR2 expression in brains of the BYHWD-treated
group is higher than the ICH group, 7 days following
stroke [24]. Radix Astragali is the main (monarch) drug
in BYHWD constituting the largest concentration of
120 g. Astragaloside IV (AS-IV) is the major active con-
stituent of Radix Astragali and has been shown to in-
duce an angiogenic response in HUVECs by enhancing
mRNA expression of VEGF and VEGFR2. This prolifera-
tion could also be suppressed by SU5416 specifically
[38]. In the present study, we found more BrdU+ nuclei
in vWF+ dilated vessels, and higher pVEGFR2 immuno-
reactivity in microvessels of BYHWD-treated animals
than those in the ICH group. These results suggested
that BYHWD was able to enhance angiogenesis and
VEGFR2 activation. Moreover, SU5416 could reverse the
effect of BYHWD on either the number of BrdU+/vWF+
vessels or the immunreactivity of p-VEGFR2. These re-
sults further suggested that BYHWD promoted angio-
genic function by enhancing VEGFR2 phosphorylation
following ICH.
VEGF and shear stress are two known factors that ini-
tiate the activation of VEGFR2 [39]. Our previous work
showed that ICH-upregulated VEGF expression could be
enhanced by BYHWD [13]. This effect has also been
identified in ischemic animal models [22]. Therefore,
VEGF increased by BYHWD may account for promoting
VEGFR2 activation. Fluid shear stress is the other major
factor that controls gene expression in vascular endothe-
lia [40,41]. High flow (strong shear stress) drives VEGF
expression to increase in parallel with its own receptor
2, and their expression presents in a time- and dose-
dependent fashion [42]. Although CBF was reduced in
the perihematomal zone and also remotely in the frontal
cortex, this was only modest and transient. This decline,
however, was resolved within 10 min and CBF restored
to the normal level after ICH [43]. BYHWD was found
Cui et al. BMC Complementary and Alternative Medicine  (2015) 15:91 Page 9 of 10effective in increasing capacity of microvascular reperfusion
and CBF [44], which might be attributed to the increase of
VEGFR2 activity.
As a sensitive and reliable indicator for detecting fore-
limb sensorimotor function, the mNSS tests were used
to assess the neurological functions of mice, including
motor ability, balancing, and alertness [45-47]. The cor-
ner turn and the food-fault test are easily performed,
sensitive and objective tests for detecting impairments of
sensorimotor function [45]. They have advantages on
testing of multiple partial sensory and motor asymmet-
ries associated with cortical or striatal dysfunction, in-
cluding vibrissae sensory, postural and limb use biases
documented in rat models [48,49]. The effects of
BYHWD on neurological outcome improvement and in-
farction reduction in ischemic stroke have been reported
[20]. In the collagenase model of hemorrhagic stroke in
rats, the resulting hematoma triggers a series of events
leading to secondary brain injury and severe neurological
deficit [27]. As indicated by both clinical and preclinical
studies, reduction of hematoma volume and decreased
tissue injury improves outcomes in ICH models [50].
Other studies uncovered that angiogenic induction pro-
motes neurogenesis, synaptogenesis, axonal sprouting and
neuroblast migration to the lesion and further contributes
to neurological recovery [51]. New vessel formation can
improve blood supply to the injured region and regenerat-
ing neurons in the injured brain [52]. As demonstrated in
our results, the improvement of neurological function in
the ICH-treated and BYHWD-treated groups was coinci-
dent with the growth in the number of BrdU+/vWF+ nuclei
and pVEGFR2-immunoreactive microvessels. In contrast,
fewer BrdU+/vWF+ cells and pVEGFR2 labeled vessels
could be observed in VEGFR inhibitor-treated counter-
parts, which showed a poor neurological outcome. This
suggests that angiogenesis plays a central role in improving
neurological function, and the pro-angiogenic effects of
BYHWD may furthermore contribute to improving the
phenotypes through boosting VEGFR2 activation.
Conclusions
In summary, our results demonstrate that the activation
of VEGFR2 plays a pivotal role in ICH-induced angiogen-
esis through the PI3K/Akt signaling pathway. Therefore,
the pro-angiogenic mechanism of BYHWD in ICH, may
partly involve the upregulation of pVEGFR2 through a
PI3K/Akt signaling mechanism.
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